Meeting
2015 ASCO Annual Meeting
A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Authors
Paul M. Barr
University of Rochester Medical Center, Rochester, NY
Paul M. Barr , Taimur Sher , Tycel Jovelle Phillips , Daniel Lebovic , Li Zhou , Jennifer Pulini , Matthew A. Spear , Andres Forero-Torres
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
EudraCT 2014-005631-13
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS8607)
DOI
10.1200/jco.2015.33.15_suppl.tps8607
Abstract #
TPS8607
Poster Bd #
422a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).
First Author: Yuankai Shi
Poster
2015 ASCO Annual Meeting
A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
First Author: Andres Forero-Torres
Poster
2014 ASCO Annual Meeting
Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.
First Author: Stephen Maxted Ansell
Poster
2011 ASCO Annual Meeting
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
First Author: B. Pro